

Mometasone Dry Powder Inhaler Formulation

Version 3.4 Revision Date: 10.10.2020 SDS Number: 437308-00012 Date of last issue: 23.03.2020
Date of first issue: 28.01.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone Dry Powder Inhaler Formulation

Manufacturer or supplier's details

Company : Organon & Co.
Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil B-2220
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com



Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Inhalation) : Category 2 (Immune system, Liver, Kidney, Skin)
Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :  

Signal Word : Danger

Hazard Statements : H360Df May damage the unborn child. Suspected of damaging fertility.
H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P273 Avoid release to the environment.

Mometasone Dry Powder Inhaler Formulation

Version 3.4 Revision Date: 10.10.2020 SDS Number: 437308-00012 Date of last issue: 23.03.2020
Date of first issue: 28.01.2016

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P391 Collect spillage.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Mometasone	83919-23-7	Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Inhalation) (Immune system, Liver, Kidney, Skin), Category 2 Long-term (chronic) aquatic hazard, Category 1	>= 10 -< 20

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : May damage the unborn child. Suspected of damaging fertility.

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

delayed		May cause damage to organs through prolonged or repeated exposure if inhaled. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Chlorine compounds
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|---|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
------------	---------	------------------------	----------------------------------	-------

SAFETY DATA SHEET



Mometasone Dry Powder Inhaler Formulation



Version 3.4 Revision Date: 10.10.2020 SDS Number: 437308-00012 Date of last issue: 23.03.2020
Date of first issue: 28.01.2016

		exposure)	concentration	
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

SAFETY DATA SHEET



Mometasone Dry Powder Inhaler Formulation



Version 3.4 Revision Date: 10.10.2020 SDS Number: 437308-00012 Date of last issue: 23.03.2020
Date of first issue: 28.01.2016

Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks.

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

Incompatible materials	:	Avoid dust formation. Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Mometasone:**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg LD50 (Mouse): > 2.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3,3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose. LC50 (Mouse): > 3,2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**Mometasone:**

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Mometasone:**

Species	:	Rabbit
Result	:	No eye irritation

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Mometasone:**

Test Type	:	Maximization Test
Routes of exposure	:	Dermal
Species	:	Guinea pig
Assessment	:	Does not cause skin sensitization.
Result	:	negative
Remarks	:	The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**Mometasone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative
--

Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive

Test Type: Mouse Lymphoma Result: negative

Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
----------------------	---	---

Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative

Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
--

Germ cell mutagenicity -	:	Weight of evidence does not support classification as a germ
--------------------------	---	--

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

Assessment cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Mometasone:**

Species : Rat
 Application Route : Inhalation
 Exposure time : 2 Years
 Dose : 0.067 mg/kg body weight
 Result : negative

Species : Mouse
 Application Route : Inhalation
 Exposure time : 19 Months
 Dose : 0.160 mg/kg body weight
 Result : negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Mometasone:**

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Subcutaneous
 Fertility: NOAEL: 0,015 mg/kg body weight
 Symptoms: Reduced embryonic survival, Reduced fetal weight.
 Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Subcutaneous
 Embryo-fetal toxicity.: LOAEL: 0,06 mg/kg body weight
 Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0,3 mg/kg body weight
 Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

Species: Rat
 Application Route: Subcutaneous
 Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
 Result: Effects on newborn.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: LOAEL: 0,7 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Components:**Mometasone:**

Routes of exposure : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Mometasone:**

Species : Rat
 NOAEL : 0,005 mg/kg
 LOAEL : 0,3 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
 LOAEL : 0,5 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

NOAEL	:	0,00013 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	:	Dog
NOAEL	:	0,0005 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Experience with human exposure**Components:****Mometasone:**

Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks	:	Dermal absorption possible
---------	---	----------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Mometasone:**

Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): 0,11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility.
		LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other	:	EC50 (Daphnia magna (Water flea)): > 5 mg/l

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

aquatic invertebrates		Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility.
		EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0,00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.
M-Factor (Chronic aquatic toxicity)	:	100
Toxicity to microorganisms	:	EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility.
		NOEC: 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility.

Persistence and degradability**Components:****Mometasone:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	:	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

Bioaccumulative potential**Components:****Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
 Bioconcentration factor (BCF): 107,1
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,68

Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4,02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
 Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
 If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
 Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3077
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
 Class : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 956
 Packing instruction (passenger aircraft) : 956
 Environmentally hazardous : yes

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

IMDG-Code

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
Hazard Identification Number	:	90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)	:	Not applicable
--	---	----------------

Brazil. List of chemicals controlled by the Federal Police	:	Not applicable
--	---	----------------

International Regulations**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.4	10.10.2020	437308-00012	Date of first issue: 28.01.2016

SECTION 16. OTHER INFORMATION**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8